Form 8-K - Current report:
SEC Accession No. 0000950170-25-089978
Filing Date
2025-06-25
Accepted
2025-06-25 16:30:29
Documents
10
Period of Report
2025-06-20
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K stro-20250620.htm   iXBRL 8-K 56909
  Complete submission text file 0000950170-25-089978.txt   166694

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT stro-20250620.xsd EX-101.SCH 29630
12 EXTRACTED XBRL INSTANCE DOCUMENT stro-20250620_htm.xml XML 4528
Mailing Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 650-392-8412
SUTRO BIOPHARMA, INC. (Filer) CIK: 0001382101 (see all company filings)

EIN.: 452441988 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38662 | Film No.: 251073985
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)